Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04871113 · ClinicalTrials.gov registry record · Phase 2
A Study to Evaluate the Antiviral Effect, Safety and Tolerability of GSK3810109A in Viremic Human Immunodeficiency Virus (HIV)-1 Infected Adults
A Phase 2 study, sponsored by ViiV Healthcare.
- Completed
- Registry status
- Phase 2
- Development phase
- 62
- Enrollment target
NCT04871113 is a Phase 2 study that has completed, run by ViiV Healthcare. The registered enrollment target is 62 participants.
The verdict
NCT04871113, a Phase 2 study, has completed, sponsored by ViiV Healthcare.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 62 participants
- Enrollment target
Study Summary
This study is to evaluate antiviral activity, efficacy, safety, tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) of GSK3810109A in HIV-1 infected treatment naive adults. Participants will receive a single dose of GSK3810109A administered either intravenously (IV) or subcutaneously (SC). The study includes a screening phase, a randomized monotherapy phase and a standard of care follow-up phase.
Interventions
- BIOLOGICAL GSK3810109A
- BIOLOGICAL Dolutegravir+lamivudine SOC regimen
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 62 participants |
| Start Date | 2021-06-22 |
| Est. Completion | 2023-09-21 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04871113
The ClinicalTrials.gov registry entry for NCT04871113 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 62 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is ViiV Healthcare, which has 182 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which GSK3810109A is the first listed.
NCT04871113 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04871113 about?
NCT04871113 is a clinical study titled "A Study to Evaluate the Antiviral Effect, Safety and Tolerability of GSK3810109A in Viremic Human Immunodeficiency Virus (HIV)-1 Infected Adults". This study is to evaluate antiviral activity, efficacy, safety, tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) of GSK3810109A in HIV-1 infected treatment naive adults. Participants will receive a single dose of GSK3810109A administered either intravenously (IV) or subcutaneously (SC)....
What is the current status of trial NCT04871113?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 62 participants. The study started on 2021-06-22. Estimated completion is 2023-09-21.
What interventions are being tested in trial NCT04871113?
The interventions under investigation include: GSK3810109A (BIOLOGICAL), Dolutegravir+lamivudine SOC regimen (BIOLOGICAL).
Who is sponsoring clinical trial NCT04871113?
This trial is sponsored by ViiV Healthcare, which has 182 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.